Effect of inhibition of α-glucosidase on age-related glucose intolerance and pancreatic atrophy in rats

Yamamoto, Masahiro; Ōtsuki, Makoto

doi:10.1016/j.metabol.2005.11.007

Cited by 37 publications

(18 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This speculation is supported by recent reports that postprandial hyperglycemia is associated with insulin resistance 19,20) and that acarbose improves insulin resistance 21,22) . In our data, a significant decrease of basal IRI in the acarbose group also might support the improvement of insulin resistance.…”

Section: Discussionmentioning

confidence: 66%

Effect of Acarbose, an Alpha-Glucosidase Inhibitor, on Serum Lipoprotein Lipase Mass Levels and Common Carotid Artery Intima-Media Thickness in Type 2 Diabetes Mellitus Treated by Sulfonylurea

Oyama

Saiki

Endoh

et al. 2008

JAT

View full text Add to dashboard Cite

Aim: Previous reports indicate that serum lipoprotein lipase mass levels (LPL mass) and common carotid artery intima-media thickness (CCA-IMT) are independent predictors of atherosclerotic diseases. The aim of this study was to examine the effects of combination therapy of sulfonylurea and acarbose on LPL mass and CCA-IMT. Methods: Eighty-four patients with type 2 diabetes mellitus, who were treated with only sulfonylureas and showed CCA-IMT of more than 0.9 mm at baseline, were selected and randomly divided into two groups. One group was administered acarbose 300 mg/day for 12 months (acarbose group, n 41), and the other group was not administered acarbose (non-acarbose group, n 43). Results: After 12 months, a significant increase in LPL mass and a significant decrease in CCA-IMT were observed in the acarbose group (1.024 to 0.964 mm), but no significant changes were observed in the non-acarbose group. In a subgroup analysis of patients with HbA1c improved by 0.5% or more, the increase of LPL mass and decrease of CCA-IMT was significantly greater in the acarbose group than in the non-acarbose group although the changes in HbA1c were similar in two groups. Conclusions: We concluded that reducing postprandial hyperglycemia might increase LPL mass levels and might be useful to prevent macroangiopathy in type 2 diabetic patients treated by sulfonylurea.

show abstract

Section: Discussionmentioning

confidence: 66%

Effect of Acarbose, an Alpha-Glucosidase Inhibitor, on Serum Lipoprotein Lipase Mass Levels and Common Carotid Artery Intima-Media Thickness in Type 2 Diabetes Mellitus Treated by Sulfonylurea

Oyama

Saiki

Endoh

et al. 2008

JAT

View full text Add to dashboard Cite

show abstract

“…Several studies have shown that inhibiting disaccharidases with inhibitors such as acarbose, miglitol and voglibose reduces postprandial hyperglycemia and ameliorates diabetes [6,7]. Thus, it is important to regulate the activities and gene expression of disaccharidases in the small intestine to inhibit postprandial hyperglycemia/hyperinsulinemia.…”

Section: Introductionmentioning

confidence: 99%

The regulation of jejunal induction of the maltase–glucoamylase gene by a high‐starch/low‐fat diet in mice

Mochizuki¹,

Honma²,

Shimada³

et al. 2010

Molecular Nutrition Food Res

View full text Add to dashboard Cite

Maltase and glucoamylase are derived from the same mRNA and are responsible for digestion of starch in the small intestine. Their jejunal activities in rodents are induced by a high-starch/low-fat (HS)-diet. However, it is unknown whether jejunal expression of the maltase-glucoamylase (Mgam) gene is enhanced by the HS-diet. In this study, we found that jejunal Mgam mRNA was increased by a HS-diet in mice. We showed that the HS-diet increased acetylation of histones, bindings of a coactivator, Creb binding protein (CREBBP), and the transcriptional factors caudal type homeobox 2 (CDX2) and HNF1 homeobox (HNF1) in the promoter/enhancer and transcriptional regions of Mgam gene. This suggests that the increase in the jejunal activity of maltase and glucoamylase caused by a HS-diet in mice is regulated at the mRNA level through histone acetylation and binding of CREBBP, CDX2 and HNF1 in the promoter/enhancer and transcriptional regions of Mgam gene.

show abstract

“…OLETF rats have been widely used for pharmacological evaluation while testing for many anti-diabetic drugs, including a Ca 2+ antagonist [73], sulfonylureas [74], an -glucosidase inhibitor [75], a thiazolidinedione [76], a biguanide (metformin) and a gluconeogenesis inhibitor [77], and a GLP-1 analog [78].…”

Section: Drug Treatment and Diabetic Complicationsmentioning

confidence: 99%

“…Wistar fatty rats have been used as a good model for evaluation of a number of anti-diabetic drugs, including a biguanide [84], an -glucosidase inhibitor [75], a thiazolidinedione [85], and an DPPIV-i [86].…”

Section: Drug Treatment and Diabetic Complicationsmentioning

confidence: 99%

Non-Obese Type 2 Diabetes Animals Models

Ishii¹,

Ohta²,

Sasase³

2012

Glucose Tolerance

View full text Add to dashboard Cite

Effect of inhibition of α-glucosidase on age-related glucose intolerance and pancreatic atrophy in rats

Cited by 37 publications

References 50 publications

Effect of Acarbose, an Alpha-Glucosidase Inhibitor, on Serum Lipoprotein Lipase Mass Levels and Common Carotid Artery Intima-Media Thickness in Type 2 Diabetes Mellitus Treated by Sulfonylurea

Effect of Acarbose, an Alpha-Glucosidase Inhibitor, on Serum Lipoprotein Lipase Mass Levels and Common Carotid Artery Intima-Media Thickness in Type 2 Diabetes Mellitus Treated by Sulfonylurea

The regulation of jejunal induction of the maltase–glucoamylase gene by a high‐starch/low‐fat diet in mice

Non-Obese Type 2 Diabetes Animals Models

Contact Info

Product

Resources

About